InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.43%
)
Bitcoin
62,960.43
(
-0.31%
)
Post# of 345969
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

freethemice

Send PM Follow Ignore
Followers 51
Posts 1681
Boards Moderated 0
Alias Born 02/15/2007

freethemice

Re: None

Wednesday, 01/30/2013 12:50:28 AM

Wednesday, January 30, 2013 12:50:28 AM

Post# of 345969
Data from another pancreatic phase II trial presented at the 2013 Gastrointestinal Cancers Symposium. This one is for TH-302 (Threshold Pharmaceuticals),
same data as presented at the ESMO meeting on Sept 29, 2012. From the abstract:
A phase 3 study of TH-302 (340 mg/m ) in combination with G is planned with OS as the primary efficacy endpoint.


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent CDMO News
More CDMO News
InvestorsHub NewsWire

Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM

ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM

North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM

VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM

Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM

Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM

Start posting your company's news
Only $200 per official company press release!